Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020

Sci Rep. 2023 Apr 12;13(1):5963. doi: 10.1038/s41598-023-32371-4.

Abstract

Targeted mass primaquine treatment (TPT) might be an effective intervention to facilitate elimination of vivax malaria in Myanmar by 2030. In this study, we explored the factors hindering coverage of a TPT campaign conducted in a malarious township of northern Myanmar. From August 2019 to July 2020, a cross-sectional exploratory design including quantitative and qualitative data was conducted in five villages with high P. vivax prevalence following a TPT campaign. Among a targeted population of 2322; 1973 (85.0%) participated in the baseline mass blood survey (MBS) and only 52.0% of the total targeted population (1208, 91.9% of total eligible population) completed the TPT. G6PD deficiency was found among 13.5% of total MBS participants and those were excluded from TPT. Of 1315 eligible samples, farmers and gold miners, males, and those aged 15 to 45 years had higher percentages of non-participation in TPT. Qualitative findings showed that most of the non-participation groups were outside the villages during TPT because of time-sensitive agricultural and other occupational or education-related purposes. In addition to mitigating of some inclusion criteria (i.e. including young children or offering weekly PQ treatment to G6PD deficient individuals), strengthening community awareness and increasing engagement should be pursued to increase community participation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials* / therapeutic use
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Glucosephosphate Dehydrogenase Deficiency*
  • Humans
  • Malaria, Vivax* / drug therapy
  • Malaria, Vivax* / epidemiology
  • Male
  • Myanmar / epidemiology
  • Primaquine / therapeutic use

Substances

  • Primaquine
  • Antimalarials